世界のジョンソン神経外胚葉症候群市場2022-2028:薬剤分類別(免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドパミンアゴニスト、その他)、疾患別、投与経路別、流通チャネル別、地域別

【英語タイトル】Global Johnson Neuroectodermal Syndrome Market Size study, by Drug Class (Immunomodulators, Interferons, Decarboxylase Inhibitors, Dopamine Agonists and Others) by Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA) and Others), by Route of Administration (Oral, Injection, Transdermal), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) and Regional Forecasts 2022-2028

Bizwit Research & Consultingが出版した調査資料(BZW22AP156)・商品コード:BZW22AP156
・発行会社(調査会社):Bizwit Research & Consulting
・発行日:2022年3月2日
・ページ数:約200
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:米国、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥693,000見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥875,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
Bizwit Research社は、2021年におよそXX億ドルであった世界のジョンソン神経外胚葉症候群市場規模が、2022年から2028年の間にXX%以上成長すると予測しています。本調査資料では、ジョンソン神経外胚葉症候群の世界市場を調査対象とし、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析(新型コロナウイルス感染症の影響)、薬剤分類別(免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドパミンアゴニスト、その他)分析、疾患別(多発性硬化症、パーキンソン病、アルツハイマー病、脊髄筋萎縮症(SMA))分析、投与経路別(経口、注射、経皮)分析、流通チャネル別(病院薬局、小売薬局、オンライン薬局)分析、地域別分析、競争分析、調査プロセスなど、以下の項目を掲載しています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析(新型コロナウイルス感染症の影響)
・世界のジョンソン神経外胚葉症候群市場規模:薬剤分類別(免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドパミンアゴニスト、その他)
・世界のジョンソン神経外胚葉症候群市場規模:疾患別(多発性硬化症、パーキンソン病、アルツハイマー病、脊髄筋萎縮症(SMA))
・世界のジョンソン神経外胚葉症候群市場規模:投与経路別(経口、注射、経皮)
・世界のジョンソン神経外胚葉症候群市場規模:流通チャネル別(病院薬局、小売薬局、オンライン薬局)
・世界のジョンソン神経外胚葉症候群市場規模:地域別
・競争分析
・調査プロセス
❖ レポートの概要 ❖

Global Johnson Neuroectodermal Syndrome Market is valued approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Johnson Neuroectodermal Syndrome is mostly characterized by hyposmia or ansomia, alopecia, conductive deafness with malformed ears and microtia. The increase in geriatric population is driving the growth for the johnson neuroectodermal syndrome market for the forecasted period. For instance, as per the World Health Organization, there were 1 billion people aged over 60 in year 2019 and this number has increased up to 1.4 billion in year 2020. And by 2050 the world’s population of people over 60 years would be doubled to 2.1 billion approx. And people aged over 80 years in between 2020 and 2050 is projected to 426 billion. Also, with the increasing research and development and innovation in treatment leads to the adoption & demand for Johnson Neuroectodermal Syndrome is likely to increase the market growth during the forecast period. However, high cost associated with the drug development might impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Johnson Neuroectodermal Syndrome market study includes Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to the favorable healthcare reimbursement policies and increased research and development. Whereas, Europe is anticipated to exhibit highest CAGR over the forecast period 2022-2028. Factors such as rising geriatric population in the region would create lucrative growth prospects for the Johnson Neuroectodermal Syndrome market across Europe region.

Major market player included in this report are:
Biogen
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Merck Sharp & Dohme Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd.
Orion Corporation.
UCB S.A.
Acadia Pharmaceuticals Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:
Immunomodulators
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others

By Disease Indication:
Multiple Sclerosis
Parkinson’s Disease
Alzheimer’s Disease
Spinal Muscular Atrophy

By Route of Administration:
Oral
Injection
Transdermal

By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Johnson Neuroectodermal Syndrome Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

❖ レポートの目次 ❖

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Billion)
1.2.1. Johnson Neuroectodermal Syndrome Market, by Region, 2020-2028 (USD Billion)
1.2.2. Johnson Neuroectodermal Syndrome Market, by Drug Class, 2020-2028 (USD Billion)
1.2.3. Johnson Neuroectodermal Syndrome Market, by Disease Indication, 2020-2028 (USD Billion)
1.2.4. Johnson Neuroectodermal Syndrome Market, by Route of Administration, 2020-2028 (USD Billion)
1.2.5. Johnson Neuroectodermal Syndrome Market, by Distribution Channel, 2020-2028 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Johnson Neuroectodermal Syndrome Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Johnson Neuroectodermal Syndrome Market Dynamics
3.1. Johnson Neuroectodermal Syndrome Market Impact Analysis (2020-2028)
3.1.1. Market Drivers
3.1.1.1. Increasing in geriatric population
3.1.2. Market Challenges
3.1.2.1. High cost associated with the drug development
3.1.3. Market Opportunities
3.1.3.1. Increasing research and development
Chapter 4. Global Johnson Neuroectodermal Syndrome Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2019-2028)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
4.5. Top investment opportunity
4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1.1. Assessment of the overall impact of COVID-19 on the industry
5.1.2. Pre COVID-19 and post COVID-19 market scenario
Chapter 6. Global Johnson Neuroectodermal Syndrome Market, by Drug Class
6.1. Market Snapshot
6.2. Global Johnson Neuroectodermal Syndrome Market by Drug Class, Performance – Potential Analysis
6.3. Global Johnson Neuroectodermal Syndrome Market Estimates & Forecasts by Drug Class 2019-2028 (USD Billion)
6.4. Johnson Neuroectodermal Syndrome Market, Sub Segment Analysis
6.4.1. Immunomodulators
6.4.2. Interferons
6.4.3. Decarboxylase Inhibitors
6.4.4. Dopamine Agonists
6.4.5. Others
Chapter 7. Global Johnson Neuroectodermal Syndrome Market, by Disease Indication
7.1. Market Snapshot
7.2. Global Johnson Neuroectodermal Syndrome Market by Disease Indication, Performance – Potential Analysis
7.3. Global Johnson Neuroectodermal Syndrome Market Estimates & Forecasts by Disease Indication 2019-2028 (USD Billion)
7.4. Johnson Neuroectodermal Syndrome Market, Sub Segment Analysis
7.4.1. Multiple Sclerosis
7.4.2. Parkinson’s Disease
7.4.3. Alzheimer’s Disease
7.4.4. Spinal Muscular Atrophy
Chapter 8. Global Johnson Neuroectodermal Syndrome Market, by Route of Administration
8.1. Market Snapshot
8.2. Global Johnson Neuroectodermal Syndrome Market by Route of Administration, Performance – Potential Analysis
8.3. Global Johnson Neuroectodermal Syndrome Market Estimates & Forecasts by Route of Administration 2019-2028 (USD Billion)
8.4. Johnson Neuroectodermal Syndrome Market, Sub Segment Analysis
8.4.1. Oral
8.4.2. Injection
8.4.3. Transdermal
Chapter 9. Global Johnson Neuroectodermal Syndrome Market, by Distribution Channel
9.1. Market Snapshot
9.2. Global Johnson Neuroectodermal Syndrome Market by Distribution Channel, Performance – Potential Analysis
9.3. Global Johnson Neuroectodermal Syndrome Market Estimates & Forecasts by Distribution Channel 2019-2028 (USD Billion)
9.4. Johnson Neuroectodermal Syndrome Market, Sub Segment Analysis
9.4.1. Hospital Pharmacy
9.4.2. Retail Pharmacy
9.4.3. Online Pharmacy
Chapter 10. Global Johnson Neuroectodermal Syndrome Market, Regional Analysis
10.1. Johnson Neuroectodermal Syndrome Market, Regional Market Snapshot
10.2. North America Johnson Neuroectodermal Syndrome Market
10.2.1. U.S. Johnson Neuroectodermal Syndrome Market
10.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2028
10.2.1.2. Disease Indication breakdown estimates & forecasts, 2019-2028
10.2.1.3. Route of Administration breakdown estimates & forecasts, 2019-2028
10.2.1.4. Distribution Channel breakdown estimates & forecasts, 2019-2028
10.2.2. Canada Johnson Neuroectodermal Syndrome Market
10.3. Europe Johnson Neuroectodermal Syndrome Market Snapshot
10.3.1. U.K. Johnson Neuroectodermal Syndrome Market
10.3.2. Germany Johnson Neuroectodermal Syndrome Market
10.3.3. France Johnson Neuroectodermal Syndrome Market
10.3.4. Spain Johnson Neuroectodermal Syndrome Market
10.3.5. Italy Johnson Neuroectodermal Syndrome Market
10.3.6. Rest of Europe Johnson Neuroectodermal Syndrome Market
10.4. Asia-Pacific Johnson Neuroectodermal Syndrome Market Snapshot
10.4.1. China Johnson Neuroectodermal Syndrome Market
10.4.2. India Johnson Neuroectodermal Syndrome Market
10.4.3. Japan Johnson Neuroectodermal Syndrome Market
10.4.4. Australia Johnson Neuroectodermal Syndrome Market
10.4.5. South Korea Johnson Neuroectodermal Syndrome Market
10.4.6. Rest of Asia Pacific Johnson Neuroectodermal Syndrome Market
10.5. Latin America Johnson Neuroectodermal Syndrome Market Snapshot
10.5.1. Brazil Johnson Neuroectodermal Syndrome Market
10.5.2. Mexico Johnson Neuroectodermal Syndrome Market
10.6. Rest of The World Johnson Neuroectodermal Syndrome Market

Chapter 11. Competitive Intelligence
11.1. Top Market Strategies
11.2. Company Profiles
11.2.1. Biogen
11.2.1.1. Key Information
11.2.1.2. Overview
11.2.1.3. Financial (Subject to Data Availability)
11.2.1.4. Product Summary
11.2.1.5. Recent Developments
11.2.2. Pfizer Inc.
11.2.3. F. Hoffmann-La Roche Ltd
11.2.4. Merck Sharp & Dohme Corp.
11.2.5. Novartis AG
11.2.6. Sanofi
11.2.7. Teva Pharmaceutical Industries Ltd.
11.2.8. Orion Corporation.
11.2.9. UCB S.A.
11.2.10. Acadia Pharmaceuticals Inc.
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
12.3. Research Assumption

List of Tables
TABLE 1. Global Johnson Neuroectodermal Syndrome Market, report scope
TABLE 2. Global Johnson Neuroectodermal Syndrome Market estimates & forecasts by Region 2019-2028 (USD Billion)
TABLE 3. Global Johnson Neuroectodermal Syndrome Market estimates & forecasts by Drug Class 2019-2028 (USD Billion)
TABLE 4. Global Johnson Neuroectodermal Syndrome Market estimates & forecasts by Disease Indication 2019-2028 (USD Billion)
TABLE 5. Global Johnson Neuroectodermal Syndrome Market estimates & forecasts by Route of Administration 2019-2028 (USD Billion)
TABLE 6. Global Johnson Neuroectodermal Syndrome Market estimates & forecasts by Distribution Channel 2019-2028 (USD Billion)
TABLE 7. Global Johnson Neuroectodermal Syndrome Market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 8. Global Johnson Neuroectodermal Syndrome Market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 9. Global Johnson Neuroectodermal Syndrome Market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 10. Global Johnson Neuroectodermal Syndrome Market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 11. Global Johnson Neuroectodermal Syndrome Market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 12. Global Johnson Neuroectodermal Syndrome Market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 13. Global Johnson Neuroectodermal Syndrome Market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 14. Global Johnson Neuroectodermal Syndrome Market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 15. Global Johnson Neuroectodermal Syndrome Market by segment, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 16. Global Johnson Neuroectodermal Syndrome Market by region, estimates & forecasts, 2019-2028 (USD Billion)
TABLE 17. U.S. Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 18. U.S. Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 19. U.S. Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 20. Canada Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 21. Canada Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 22. Canada Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 23. UK Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 24. UK Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 25. UK Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 26. Germany Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 27. Germany Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 28. Germany Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 29. RoE Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 30. RoE Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 31. RoE Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 32. China Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 33. China Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 34. China Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 35. India Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 36. India Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 37. India Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 38. Japan Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 39. Japan Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 40. Japan Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 41. RoAPAC Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 42. RoAPAC Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 43. RoAPAC Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 44. Brazil Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 45. Brazil Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 46. Brazil Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 47. Mexico Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 48. Mexico Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 49. Mexico Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 50. RoLA Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 51. RoLA Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 52. RoLA Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 53. Row Johnson Neuroectodermal Syndrome Market estimates & forecasts, 2019-2028 (USD Billion)
TABLE 54. Row Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 55. Row Johnson Neuroectodermal Syndrome Market estimates & forecasts by segment 2019-2028 (USD Billion)
TABLE 56. List of secondary Disease Indications, used in the study of global Johnson Neuroectodermal Syndrome Market
TABLE 57. List of primary Disease Indications, used in the study of global Johnson Neuroectodermal Syndrome Market
TABLE 58. Years considered for the study
TABLE 59. Exchange rates considered

List of figures
FIG 1. Global Johnson Neuroectodermal Syndrome Market, research methodology
FIG 2. Global Johnson Neuroectodermal Syndrome Market, market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global Johnson Neuroectodermal Syndrome Market, key trends 2021
FIG 5. Global Johnson Neuroectodermal Syndrome Market, growth prospects 2022-2028
FIG 6. Global Johnson Neuroectodermal Syndrome Market, porters 5 force model
FIG 7. Global Johnson Neuroectodermal Syndrome Market, pest analysis
FIG 8. Global Johnson Neuroectodermal Syndrome Market, value chain analysis
FIG 9. Global Johnson Neuroectodermal Syndrome Market by segment, 2019 & 2028 (USD Billion)
FIG 10. Global Johnson Neuroectodermal Syndrome Market by segment, 2019 & 2028 (USD Billion)
FIG 11. Global Johnson Neuroectodermal Syndrome Market by segment, 2019 & 2028 (USD Billion)
FIG 12. Global Johnson Neuroectodermal Syndrome Market by segment, 2019 & 2028 (USD Billion)
FIG 13. Global Johnson Neuroectodermal Syndrome Market by segment, 2019 & 2028 (USD Billion)
FIG 14. Global Johnson Neuroectodermal Syndrome Market, regional snapshot 2019 & 2028
FIG 15. North America Johnson Neuroectodermal Syndrome Market 2019 & 2028 (USD Billion)
FIG 16. Europe Johnson Neuroectodermal Syndrome Market 2019 & 2028 (USD Billion)
FIG 17. Asia pacific Johnson Neuroectodermal Syndrome Market 2019 & 2028 (USD Billion)
FIG 18. Latin America Johnson Neuroectodermal Syndrome Market 2019 & 2028 (USD Billion)
FIG 19. Global Johnson Neuroectodermal Syndrome Market, company market share analysis (2021)

















★調査レポート[世界のジョンソン神経外胚葉症候群市場2022-2028:薬剤分類別(免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドパミンアゴニスト、その他)、疾患別、投与経路別、流通チャネル別、地域別] (コード:BZW22AP156)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のジョンソン神経外胚葉症候群市場2022-2028:薬剤分類別(免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドパミンアゴニスト、その他)、疾患別、投与経路別、流通チャネル別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆